-
Subject Areas on Research
-
211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y.
-
A Bayesian hierarchical approach for combining case-control and prospective studies.
-
A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer.
-
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
-
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.
-
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
-
A Redox-active Mn Porphyrin, MnTnBuOE-2-PyP5+, Synergizes with Carboplatin in Treatment of Chemoresistant Ovarian Cell Line.
-
A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer.
-
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk.
-
A branching process model of ovarian cancer.
-
A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
-
A comparison of least squares and conditional maximum likelihood estimators under volume endpoint censoring in tumor growth experiments.
-
A complementary care study combining flaxseed oil, caffeine, fasting, and exercise in women diagnosed with advanced ovarian cancer: findings from a case study.
-
A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants.
-
A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.
-
A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus.
-
A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer.
-
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.
-
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.
-
A latent model for prioritization of SNPs for functional studies.
-
A model to predict risk of blood transfusion after gynecologic surgery.
-
A multi-center population-based case-control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES).
-
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer.
-
A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
-
A penalized likelihood approach for investigating gene-drug interactions in pharmacogenetic studies.
-
A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy.
-
A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
-
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
-
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
-
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
-
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
-
A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.
-
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
-
A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
-
A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase-2.
-
A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
-
A region of interstitial 17q25 allelic loss in ovarian tumors coincides with a defined region of loss in breast tumors.
-
A review of cost-effectiveness studies in ovarian cancer.
-
A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase.
-
A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer.
-
A targeted genetic association study of epithelial ovarian cancer susceptibility.
-
ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.
-
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
-
ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium.
-
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.
-
ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers.
-
ARID1A-mutated ovarian cancers depend on HDAC6 activity.
-
ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer.
-
Abdominal pain and a pelvic mass.
-
Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers.
-
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
-
Acquisition of a side population fraction augments malignant phenotype in ovarian cancer.
-
Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility.
-
Acute leukemia in Burkitt lymphoma.
-
Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
-
Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer.
-
Adherence to PARP inhibitor therapy among women with ovarian cancer.
-
Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation.
-
Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes.
-
Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging.
-
Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging.
-
Adnexal Masses in Pregnancy.
-
Adnexal masses: MR imaging observations at 1.5 T, with US and CT correlation.
-
Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.
-
Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth.
-
Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study.
-
Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.
-
Advanced stage primary mucinous ovarian carcinoma. Where do we stand ?
-
Age at diagnosis and multiple primary cancers of the breast and ovary.
-
Age at natural menopause and the risk of epithelial ovarian cancer.
-
Allele loss on chromosome 1p36 in epithelial ovarian cancers.
-
Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors.
-
An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer.
-
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
-
An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene.
-
An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
-
An integrated molecular profile of endometrioid ovarian cancer.
-
Analgesic drug use and risk of ovarian cancer.
-
Analgesic medication use and risk of epithelial ovarian cancer in African American women.
-
Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.
-
Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome.
-
Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression.
-
Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women.
-
Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
-
Antiangiogenic therapies in epithelial ovarian cancer.
-
Anticipatory immune suppression and nausea in women receiving cyclic chemotherapy for ovarian cancer.
-
Antidepressant medication use [corrected] and risk of ovarian cancer.
-
Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.
-
Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
-
Are Videos or Text Better for Describing Attributes in Stated-Preference Surveys?
-
Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.
-
Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells.
-
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.
-
Assessing the genetic architecture of epithelial ovarian cancer histological subtypes.
-
Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors.
-
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).
-
Assessment of hepatocyte growth factor in ovarian cancer mortality.
-
Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study.
-
Assessment of small in-frame indels and C-terminal nonsense variants of BRCA1 using a validated functional assay.
-
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.
-
Association Between Breastfeeding and Ovarian Cancer Risk.
-
Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk.
-
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
-
Association between Body Powder Use and Ovarian Cancer: The African American Cancer Epidemiology Study (AACES).
-
Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer.
-
Association between IHC and MSI testing to identify mismatch repair-deficient patients with ovarian cancer.
-
Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer.
-
Association between endometriosis and gynecological cancers: a critical review of the literature.
-
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
-
Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study.
-
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.
-
Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.
-
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.
-
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
-
Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer.
-
Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study.
-
Associations of Healthcare Affordability, Availability, and Accessibility with Quality Treatment Metrics in Patients with Ovarian Cancer.
-
Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.
-
Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.
-
Availability of healthcare resources and epithelial ovarian cancer stage of diagnosis and mortality among Blacks and Whites.
-
Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.
-
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.
-
BAP1 Tumor Predisposition Syndrome Presenting as a Recurrent Ovarian Sex Cord-Stromal Tumor.
-
BAX-mediated cell death affects early germ cell loss and incidence of testicular teratomas in Dnd1(Ter/Ter) mice.
-
BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.
-
BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION: A CASE REPORT.
-
BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.
-
BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
-
BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
-
BRCA1 maps proximal to D17S579 on chromosome 17q21 by genetic analysis.
-
BRCA1 mutations in primary breast and ovarian carcinomas.
-
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
-
BRCA2 monoclonal antibodies react with differentiating epithelium.
-
BRCA2 mutations in primary breast and ovarian cancers.
-
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
-
BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells.
-
Bayesian joint analysis of heterogeneous genomics data.
-
Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case-control study.
-
Biomarkers in the ovary.
-
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes.
-
Breast and ovarian cancer in the older woman.
-
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
-
Breast carcinoma masquerading as primary ovarian neoplasm.
-
CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer.
-
CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation.
-
CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.
-
CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion.
-
CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
-
CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.
-
CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.
-
COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies.
-
CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.
-
Cabozantinib in ovarian clear cell cancers: UnMET expectations.
-
Can we maximize both value and quality in gynecologic cancer care? A work in progress.
-
Cancer recurrence and hyperglycemia with dexamethasone for postoperative nausea and vomiting prophylaxis: more moot points?
-
Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk.
-
Carcinoid metastatic to the ovary. A clinocopathologic analysis of 35 cases.
-
Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES).
-
Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.
-
Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene.
-
Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.
-
Cell growth regulation in epithelial ovarian cancer.
-
Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci.
-
Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
-
Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2.
-
Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls.
-
Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature.
-
Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer.
-
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.
-
Chemotherapy administration for ovarian cancer by gynecologic oncologists and medical oncologists.
-
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.
-
Chemotherapy-induced apoptosis in epithelial ovarian cancers.
-
Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
-
Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium.
-
Cigarette smoking and epithelial ovarian cancer by histologic type.
-
Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies.
-
Cigarette smoking and the association with serous ovarian cancer in African American women: African American Cancer Epidemiology Study (AACES).
-
Cigarette smoking and the risk of female reproductive cancer.
-
Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies.
-
Circulating Biomarkers of Inflammation and Ovarian Cancer Risk in the Nurses' Health Studies.
-
Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study.
-
Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer.
-
Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line.
-
Clear-cell adenocarcinoma of the vagina and cervix in young females: analysis of 37 tumors that persisted or recurred after primary therapy.
-
Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.
-
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
-
Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation.
-
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.
-
Coexistence of a chemotactic factor and a retroviral P15E-related chemotaxis inhibitor in human tumor cell culture supernatants.
-
Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues.
-
Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study.
-
Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection.
-
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
-
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
-
Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer.
-
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.
-
Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk.
-
Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions.
-
Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer.
-
Common variants at 19p13 are associated with susceptibility to ovarian cancer.
-
Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer.
-
Common variation in Nemo-like kinase is associated with risk of ovarian cancer.
-
Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer.
-
Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer.
-
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.
-
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
-
Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group study.
-
Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models.
-
Comprehensive molecular portraits of human breast tumours.
-
Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma.
-
Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice.
-
Conseusus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO.
-
Consortium analysis of 7 candidate SNPs for ovarian cancer.
-
Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.
-
Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells.
-
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
-
Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium.
-
Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.
-
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
-
Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer.
-
Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
-
Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer.
-
Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
-
Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
-
Cost-Effectiveness of Venous Thromboembolism Prophylaxis During Neoadjuvant Chemotherapy for Ovarian Cancer.
-
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
-
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
-
Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery.
-
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
-
Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery.
-
Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer.
-
Cost-effectiveness of management strategies for patients with recurrent ovarian cancer and inoperable malignant bowel obstruction.
-
Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention.
-
Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
-
Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer.
-
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.
-
Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers.
-
Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.
-
Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery.
-
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup.
-
Cyclin E overexpression relates to ovarian cancer histology but not to risk factors.
-
Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and ovarian cancer risk: a meta-analysis.
-
Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.
-
Cytologic studies of glucose-6-phosphate dehydrogenase in malignancy.
-
DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization.
-
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
-
Dairy, calcium, vitamin D and ovarian cancer risk in African-American women.
-
Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
-
Death-associated protein kinase 1 promotes growth of p53-mutant cancers.
-
Delayed treatment of papillary thyroid carcinoma arising from struma ovarii in a patient with history of bilateral salpingo-oophorectomy: a case report.
-
Demographic, presentation, and treatment factors and racial disparities in ovarian cancer hospitalization outcomes.
-
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.
-
Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins.
-
Desmoplastic small round cell tumor masquerading as advanced ovarian cancer.
-
Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test.
-
Determination of proliferation index in advanced ovarian cancer using quantitative image analysis.
-
Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis.
-
Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment.
-
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).
-
Development of a multimarker assay for early detection of ovarian cancer.
-
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction.
-
Dietary Quality and Ovarian Cancer Risk in African-American Women.
-
Dietary carbohydrate intake, glycaemic load, glycaemic index and ovarian cancer risk in African-American women.
-
Dietary inflammatory index and risk of epithelial ovarian cancer in African American women.
-
Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells.
-
Differential Expression of KRAS and SIRT1 in Ovarian Cancers with and Without Endometriosis.
-
Differential expression of immune related genes in high-grade ovarian serous carcinoma.
-
Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas.
-
Differential platelet levels affect response to taxane-based therapy in ovarian cancer.
-
Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells.
-
Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity.
-
Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.
-
Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study.
-
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
-
Double agents in the war on cancer: leukocytes govern ovarian cancer progression.
-
Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
-
Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.
-
Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
-
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis.
-
ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.
-
ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study.
-
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
-
Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment.
-
Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer.
-
Effect of Cultural, Folk, and Religious Beliefs and Practices on Delays in Diagnosis of Ovarian Cancer in African American Women.
-
Effect of carbon dioxide on human ovarian carcinoma cell growth.
-
Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis?
-
Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy.
-
Effects of risk factors for ovarian cancer in women with and without endometriosis.
-
Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
-
Elevated serum CA-125 levels: hepatitis or ascites?
-
Elevation of multiple serum markers in patients with stage I ovarian cancer.
-
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.
-
Endocervical-like (Müllerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation.
-
Endogenous RGS proteins attenuate Galpha(i)-mediated lysophosphatidic acid signaling pathways in ovarian cancer cells.
-
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
-
Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer.
-
Enhanced uptake of a thermally responsive polypeptide by tumor cells in response to its hyperthermia-mediated phase transition.
-
Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.
-
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.
-
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor.
-
Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia.
-
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer.
-
Epigenetic determinants of ovarian clear cell carcinoma biology.
-
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
-
Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer.
-
Epithelial ovarian cancer risk among women with polycystic ovary syndrome.
-
Epithelial ovarian cancer.
-
Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk.
-
Erythropoietin Stimulates Tumor Growth via EphB4.
-
Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
-
Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
-
Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach.
-
Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored.
-
Estrogen bioactivation, genetic polymorphisms, and ovarian cancer.
-
Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium.
-
European American stratification in ovarian cancer case control data: the utility of genome-wide data for inferring ancestry.
-
Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship.
-
Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study.
-
Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses.
-
Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers.
-
Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
-
Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot".
-
Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.
-
Evaluation of markers and risk prediction models: overview of relationships between NRI and decision-analytic measures.
-
Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.
-
Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin.
-
Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen.
-
Evidence of a genetic link between endometriosis and ovarian cancer.
-
Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk.
-
Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies.
-
Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines.
-
Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma.
-
Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.
-
Expression signatures of TP53 mutations in serous ovarian cancers.
-
FDG-PET for management of cervical and ovarian cancer.
-
FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway.
-
Facilitated cascade testing (FaCT): a randomized controlled trial.
-
Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2.
-
Familial ovarian cancer: a population-based case-control study.
-
Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death.
-
Fertility drugs and ovarian cancer risk: a critical review of the literature.
-
Fertility drugs and risk of ovarian cancer: dispelling the myth.
-
Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.
-
Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer.
-
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
-
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.
-
Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis.
-
Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.
-
Frequency of breast cancer attributable to BRCA1 in a population-based series of American women.
-
Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
-
Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer.
-
Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.
-
Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy.
-
Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus.
-
Functional Annotation Signatures of Disease Susceptibility Loci Improve SNP Association Analysis
-
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
-
G6PD inhibition sensitizes ovarian cancer cells to oxidative stress in the metastatic omental microenvironment.
-
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.
-
Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin.
-
Gene expression patterns that characterize advanced stage serous ovarian cancers.
-
Gene expression profiling in RAS oncogene-transformed cell lines and in solid tumors using subtractive suppression hybridization and cDNA arrays.
-
Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer.
-
Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes.
-
Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.
-
Genes with bimodal expression are robust diagnostic targets that define distinct subtypes of epithelial ovarian cancer with different overall survival.
-
Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk.
-
Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations.
-
Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want?
-
Genetic instability of microsatellites in endometrial carcinoma.
-
Genetic susceptibility testing and prophylactic oophorectomy.
-
Genetic testing in ovarian cancer: getting better, and maybe not just for disease susceptibility anymore.
-
Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium.
-
Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk.
-
Genetic variation in the one-carbon transfer pathway and ovarian cancer risk.
-
Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
-
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
-
Genetic/familial high-risk assessment: breast and ovarian.
-
Genetic/familial high-risk assessment: breast and ovarian.
-
Genetically predicted circulating protein biomarkers and ovarian cancer risk.
-
Genetics and women's health issues--the commitment of EMS to women scientists and gender-associated disease topics.
-
Genital Powder Use and Risk of Epithelial Ovarian Cancer in the Ovarian Cancer in Women of African Ancestry Consortium.
-
Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls.
-
Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.
-
Genome-scale screen for DNA methylation-based detection markers for ovarian cancer.
-
Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.
-
Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
-
Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women.
-
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.
-
Genome-wide significant risk associations for mucinous ovarian carcinoma.
-
Genomic sweeping for hypermethylated genes.
-
Genomic tests for ovarian cancer detection and management.
-
Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.
-
Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.
-
Global ovarian cancer health disparities.
-
Glutathione S-transferase M1, T1, and P1 polymorphisms and ovarian cancer risk: a meta-analysis.
-
Goblet-cell mucinous epithelium lining the endometrium and endocervix: evidence of metastasis from an appendiceal primary tumor through the use of cytokeratin-7 and -20 immunostains.
-
Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines.
-
Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro.
-
Growth regulation and transformation of ovarian epithelium.
-
HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.
-
HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer.
-
Ha-ras polymorphisms in epithelial ovarian cancer.
-
Health economics of screening for gynaecological cancers.
-
Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.
-
Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study.
-
Healthcare Access Domains Mediate Racial Disparities in Ovarian Cancer Treatment Quality in a US Patient Cohort: A Structural Equation Modelling Analysis.
-
Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma.
-
Hepatoid yolk sac tumor of the ovary (endodermal sinus tumor with hepatoid differentiation): a light microscopic, ultrastructural and immunohistochemical study of seven cases.
-
Heterogeneity of antigen expression in advanced epithelial ovarian cancer.
-
High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.
-
High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
-
High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.
-
High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
-
High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer.
-
High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer.
-
High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer.
-
History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium.
-
History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.
-
History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report.
-
Histotype classification of ovarian carcinoma: A comparison of approaches.
-
Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women.
-
Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
-
Human ovarian cancer of the surface epithelium.
-
Human ovarian cancers express somatostatin receptors.
-
Hydrops fetalis associated with idiopathic arterial calcification.
-
Hypertensive reactions associated with paclitaxel.
-
Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size.
-
Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancers.
-
Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression.
-
IL-6 and ovarian cancer--letter.
-
IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity.
-
ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation.
-
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.
-
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
-
Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer.
-
Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes.
-
Identification of genes associated with ovarian cancer metastasis using microarray expression analysis.
-
Identification of six new susceptibility loci for invasive epithelial ovarian cancer.
-
Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer.
-
Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?
-
IgA transcytosis and antigen recognition govern ovarian cancer immunity.
-
Immunotherapy for gynaecological malignancies.
-
Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
-
Impact of Medicaid expansion on women with gynecologic cancer: a difference-in-difference analysis.
-
Impact of Patents and Licensing Practices on Access to Genetic Testing for Inherited Susceptibility to Cancer: Comparing Breast and Ovarian Cancers to Colon Cancers
-
Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer.
-
Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
-
Impact of hysterectomy and bilateral oophorectomy prevalence on rates of cervical, uterine, and ovarian cancer among American Indian and Alaska Native women, 1999-2004.
-
Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk.
-
Impact of the Cancer Risk Intake System on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy.
-
Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery.
-
Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention.
-
In reply.
-
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.
-
In vitro fertilization and embryo transfer (IVF/ET): an established and successful therapy for endometriosis.
-
Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
-
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.
-
Increased levels of laminin in ascitic fluid of patients with ovarian cancer.
-
Increased risk for familial ovarian cancer among Jewish women: a population-based case-control study.
-
Increased serum levels of macrophage colony-stimulating factor in ovarian cancer.
-
Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
-
Individual, Social, and Societal Correlates of Health-Related Quality of Life Among African American Survivors of Ovarian Cancer: Results from the African American Cancer Epidemiology Study.
-
Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody.
-
Inherited determinants of ovarian cancer survival.
-
Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration.
-
Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk.
-
Inherited variants in regulatory T cell genes and outcome of ovarian cancer.
-
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
-
Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells.
-
Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
-
Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
-
Insular carcinoid of ovary associated with malignant mucinous tumors.
-
Insular carcinoid primary in the ovary. A clinicopathologic analysis of 48 cases.
-
Insurance coverage among women diagnosed with a gynecologic malignancy before and after implementation of the Affordable Care Act.
-
Integrated genomic analyses of ovarian carcinoma.
-
Integrated genomic characterization of endometrial carcinoma.
-
Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci.
-
Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance.
-
Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas.
-
Interphase fluorescence in situ hybridization for trisomy 12 on archival ovarian sex cord-stromal tumors.
-
Intestinal obstruction in patients with ovarian cancer. Variables associated with surgical complications and survival.
-
Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma.
-
Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
-
Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma.
-
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
-
Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
-
Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer.
-
Is There a Role for Ovarian Cancer Screening in High-Risk Women?
-
Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis.
-
Is stromal microinvasion in primary mucinous ovarian tumors with "mucin granuloma" true invasion?
-
K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.
-
Kernel canonical correlation analysis for assessing gene-gene interactions and application to ovarian cancer.
-
LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer.
-
Labeling a TCO-functionalized single domain antibody fragment with 18F via inverse electron demand Diels Alder cycloaddition using a fluoronicotinyl moiety-bearing tetrazine derivative.
-
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.
-
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.
-
Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells.
-
Letter: Treatment of dysgerminoma.
-
Lifetime number of ovulatory cycles and epithelial ovarian cancer risk in African American women.
-
Lipomatous uterine masses: potential to mimic ovarian dermoids on endovaginal sonography.
-
Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.
-
Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center.
-
Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma.
-
Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.
-
Loss of betaglycan expression in ovarian cancer: role in motility and invasion.
-
Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
-
Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas.
-
Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.
-
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
-
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
-
Lymph node sampling in patients with epithelial ovarian carcinoma.
-
Lymphomas or leukemia presenting as ovarian tumors. An analysis of 42 cases.
-
Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells.
-
MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.
-
MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.
-
Main principles and outcomes of DNA methylation analysis.
-
Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
-
Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?
-
Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types.
-
Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?
-
Malignant struma ovarii: a blinded study of 86 cases assessing which histologic features correlate with aggressive clinical behavior.
-
Malignant struma ovarii: a population-level analysis of a large series of 68 patients.
-
Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread.
-
Malignant transformation of ovarian epithelium.
-
Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database.
-
Management of adnexal mass.
-
Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices.
-
Management of incidental ovarian tumors in patients undergoing gastric bypass.
-
Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
-
Managing hereditary ovarian cancer risk.
-
Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
-
Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer.
-
Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines.
-
Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer.
-
Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.
-
Menopausal hormones and risk of ovarian cancer.
-
Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium.
-
Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors.
-
Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers.
-
Methods, safety, and early clinical outcomes of dose escalation using simultaneous integrated and sequential boosts in patients with locally advanced gynecologic malignancies.
-
Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer.
-
MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium.
-
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.
-
Microarray analysis of gene expression in gynecologic cancers--still only the beginning.
-
Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers.
-
Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity.
-
Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer.
-
Mitochondrial Superoxide Dismutase Has a Protumorigenic Role in Ovarian Clear Cell Carcinoma.
-
Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity.
-
Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.
-
Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.
-
Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.
-
Molecular approaches to prevention and detection of epithelial ovarian cancer.
-
Molecular aspects of ovarian cancer.
-
Molecular genetic features of ovarian cancer.
-
Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors.
-
Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.
-
Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.
-
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.
-
Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
-
Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
-
Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
-
Mutations of the E-cadherin gene in human gynecologic cancers.
-
Mycobacterium bovis peritonitis mimicking ovarian cancer in a young woman.
-
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
-
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.
-
Nanomolecular targeting of dendritic cells for ovarian cancer therapy.
-
Natural history of biologically malignant struma ovarii: analysis of 27 cases with extraovarian spread.
-
Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk.
-
Neurohormonal peptides in ovarian carcinoids: an immunohistochemical study of 81 primary carcinoids and of intraovarian metastases from six mid-gut carcinoids.
-
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
-
Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth.
-
No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.
-
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
-
No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.
-
No stone left unturned: challenges encountered during recruitment of women with advanced ovarian cancer for a phase I study.
-
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.
-
Nonsteroidal antiinflammatory drugs and progestins synergistically enhance cell death in ovarian epithelial cells.
-
Notch3 pathway alterations in ovarian cancer.
-
Novel Therapies in Gynecologic Cancer.
-
OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
-
OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
-
Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium.
-
Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.
-
Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer.
-
Obesity, weight gain, and ovarian cancer risk in African American women.
-
Obesity: Too big a problem to ignore.
-
Observations on the intraperitoneal distribution of chromic phosphate (32P) suspension for intraperitoneal therapy.
-
Obstetrics and Gynecology Residents Can Accurately Classify Benign Ovarian Tumors Using the International Ovarian Tumor Analysis Rules.
-
Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies.
-
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
-
Omental cakes in American Burkitt lymphoma. Computed tomography demonstration.
-
Oncogenes in ovarian cancer.
-
Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
-
Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma.
-
Opportunities to Advance the Delivery of High-Quality, Goal-Concordant End-of-Life Care in Ovarian Cancer.
-
Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle.
-
Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis.
-
Oral contraceptive pills. Prevention of ovarian cancer and other benefits.
-
Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review.
-
Oral contraceptive use and risk of cancer--response.
-
Oral contraceptive use for the primary prevention of ovarian cancer.
-
Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis.
-
Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
-
Ovarian Cancer Epidemiology, Healthcare Access and Disparities (ORCHiD): methodology for a population-based study of black, Hispanic and white patients with ovarian cancer.
-
Ovarian Cancer in Women of African Ancestry (OCWAA) consortium: a resource of harmonized data from eight epidemiologic studies of African American and white women.
-
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
-
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
-
Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management.
-
Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
-
Ovarian cancer epidemiology in the era of collaborative team science.
-
Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells.
-
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.
-
Ovarian cancer risk associated with inherited inflammation-related variants.
-
Ovarian cancer risk factors in African-American and white women.
-
Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium.
-
Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype.
-
Ovarian cancer, version 2.2013.
-
Ovarian cancer, version 3.2012.
-
Ovarian cancer. Clinical practice guidelines in oncology.
-
Ovarian cancer: time to move beyond one size fits all.
-
Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells.
-
Ovarian teratoma with glial implants on the peritoneum. An analysis of 12 cases.
-
Overexpression and mutation of p53 in epithelial ovarian cancer.
-
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
-
Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
-
Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas.
-
Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States).
-
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
-
PILAR is a novel modulator of human T-cell expansion.
-
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
-
Pathogenesis of ovarian cancers.
-
Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer.
-
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
-
Pathology of epithelial ovarian tumors.
-
Pathway-Structured Predictive Model for Cancer Survival Prediction: A Two-Stage Approach.
-
Patient and primary care provider experience using a family health history collection, risk stratification, and clinical decision support tool: a type 2 hybrid controlled implementation-effectiveness trial.
-
Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.
-
Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
-
Patient preferences in advanced or recurrent ovarian cancer.
-
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
-
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
-
Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies.
-
Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study.
-
Performance of amplified DNA in an Illumina GoldenGate BeadArray assay.
-
Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer.
-
Peritoneal carcinomatosis: preoperative CT with intraperitoneal contrast material.
-
Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy.
-
Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.
-
Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia.
-
Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen.
-
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103).
-
Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
-
Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy.
-
Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
-
Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.
-
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.
-
Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
-
Phosphorus-based SAHA analogues as histone deacetylase inhibitors.
-
Ploidy analysis of epithelial ovarian cancers using image cytometry.
-
Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium.
-
Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.
-
Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium.
-
Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women.
-
Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
-
Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.
-
Polymorphisms in TCEAL7 and risk of epithelial ovarian cancer.
-
Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium.
-
Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer.
-
Polymorphisms in the kinesin-like factor 1 B gene and risk of epithelial ovarian cancer in Eastern Chinese women.
-
Pooling of case specimens to create standard serum sets for screening cancer biomarkers.
-
Population distribution of lifetime risk of ovarian cancer in the United States.
-
Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer.
-
Potential of CT-scan based tumor volume as a response indicator in chemotherapy of advanced epithelial ovarian cancer.
-
Potentially functional variants in nucleotide excision repair pathway genes predict platinum treatment response of Chinese ovarian cancer patients.
-
Pre-counseling education materials for BRCA testing: does tailoring make a difference?
-
Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study.
-
Pre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome.
-
Prediagnostic Proinflammatory Dietary Potential Is Associated with All-Cause Mortality among African-American Women with High-Grade Serous Ovarian Carcinoma.
-
Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals.
-
Predicting non-home discharge in epithelial ovarian cancer patients: External validation of a predictive model.
-
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
-
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
-
Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
-
Predictors of clinical outcomes in the laparoscopic management of adnexal masses.
-
Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.
-
Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.
-
Pregnancy recency and risk of ovarian cancer.
-
Premenopausal Hysterectomy and Risk of Ovarian Cancer in African-American Women.
-
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
-
Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines.
-
Primary chemotherapy in epithelial ovarian cancer.
-
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
-
Primary peritoneal and ovarian cancers: an epidemiological comparative analysis.
-
Primary trabecular carcinoid of the ovary.
-
Primary treatment of advanced ovarian cancer: how does the 'real world' practice?
-
Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.
-
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
-
Progesterone receptor gene polymorphism and risk for breast and ovarian cancer.
-
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.
-
Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis.
-
Prognostic factors in early-onset epithelial ovarian cancer: a population-based study.
-
Prognostic gene expression signature for high-grade serous ovarian cancer.
-
Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
-
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
-
Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis.
-
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer.
-
Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin.
-
Prostaglandin F2alpha levels in human ovarian plasma in pregnancy and in a case of Halban's disease.
-
Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer.
-
Psychosocial factors associated with genetic testing status among African American women with ovarian cancer: Results from the African American Cancer Epidemiology Study.
-
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.
-
Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial.
-
Quality of life in ICON7: need for patients' perspectives.
-
Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.
-
Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.
-
Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.
-
Race Differences in the Associations between Menstrual Cycle Characteristics and Epithelial Ovarian Cancer.
-
Race, Affordability and Utilization of Supportive Care in Ovarian Cancer Patients.
-
Racial Differences in Population Attributable Risk for Epithelial Ovarian Cancer in the OCWAA Consortium.
-
Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma.
-
Racial differences in the association of body mass index and ovarian cancer risk in the OCWAA Consortium.
-
Racial disparities in epithelial ovarian cancer survival: An examination of contributing factors in the Ovarian Cancer in Women of African Ancestry consortium.
-
Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies.
-
Racial/ethnic disparities in ovarian cancer research.
-
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
-
Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution.
-
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
-
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
-
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
-
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
-
Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients.
-
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
-
Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
-
Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium.
-
Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii.
-
Recombinant polyclonal antibody libraries.
-
Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials.
-
Recreational physical activity and ovarian cancer risk and survival.
-
Recreational physical activity and ovarian cancer risk in African American women.
-
Recreational physical activity and survival in African-American women with ovarian cancer.
-
Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium.
-
Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
-
Reduction of ovarian and oviductal cancers in calorie-restricted laying chickens.
-
Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta.
-
Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta.
-
Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.
-
Regulator of G-protein signalling expression and function in ovarian cancer cell lines.
-
Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells.
-
Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones.
-
Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.
-
Relationship of epithelial ovarian cancer to other malignancies within families.
-
Reply to 'Comment on 'Dairy, calcium, vitamin D and ovarian cancer risk in African-American women''.
-
Reproductive Factors Do Not Influence Survival with Ovarian Cancer.
-
Reproductive factors and ovarian cancer risk in African-American women.
-
Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer.
-
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
-
Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers.
-
Rethinking ovarian cancer: recommendations for improving outcomes.
-
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
-
Rigor in Quality Improvement Studies and the Role of Time-Series Methodologies.
-
Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci.
-
Risk factors for ovarian cancers with and without microsatellite instability.
-
Risk factors for ovarian cancers with and without microsatellite instability.
-
Risk of benign gynecologic tumors in relation to prenatal diethylstilbestrol exposure.
-
Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
-
Risk of ovarian cancer and inherited variants in relapse-associated genes.
-
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.
-
Risk-Reducing Salpingectomy Versus Standard Tubal Sterilization: Lessons From Offering Women Options for Interval Sterilization.
-
Risks and Benefits of Salpingectomy at the Time of Sterilization.
-
Role of BRCA1 mutation screening in the management of familial ovarian cancer.
-
Role of Increased n-acetylaspartate Levels in Cancer.
-
Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
-
Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC).
-
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
-
Role of eotaxin-1 signaling in ovarian cancer.
-
Role of genetic polymorphisms and ovarian cancer susceptibility.
-
Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium.
-
Role of salpingectomy at the time of urogynecologic surgery.
-
Role of vascular leukocytes in ovarian cancer neovascularization.
-
Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer.
-
SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm.
-
SPHK1 Is a Novel Target of Metformin in Ovarian Cancer.
-
Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.
-
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
-
Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer.
-
Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells.
-
Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression.
-
Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada--Clinical Trials Group (NCIC-CTG).
-
Second-look operation for epithelial ovarian cancer: laparoscopy or laparotomy?
-
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
-
Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
-
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
-
Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis.
-
Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer.
-
Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.
-
Shared genetics underlying epidemiological association between endometriosis and ovarian cancer.
-
Shared heritability and functional enrichment across six solid cancers.
-
Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer.
-
Simultaneous endometrial malignant mixed mesodermal tumor and ovarian serous adenocarcinoma.
-
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer.
-
Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.
-
Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: surgical outcomes and learning curve analysis.
-
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
-
Socioeconomic Status in Relation to the Risk of Ovarian Cancer in African-American Women: A Population-Based Case-Control Study.
-
Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
-
Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.
-
Some mullerian inclusion cysts in lymph nodes may sometimes be metastases from serous borderline tumors of the ovary.
-
Sonography of benign cystic teratoma of the ovary: pitfalls in diagnosis.
-
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
-
Specific keynote: genome copy number abnormalities in ovarian cancer.
-
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
-
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer.
-
Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.
-
Steroid secretion and testosterone binding in a woman with an ovarian hilus cell tumor and thyrotoxicosis.
-
Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.
-
Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha.
-
Stretching the surface epithelium.
-
Strumal carcinoid of the ovary: an analysis of 50 cases of a distinctive tumor composed of thyroid tissue and carcinoid.
-
Supplemental Selenium May Decrease Ovarian Cancer Risk in African-American Women.
-
Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer.
-
Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines.
-
Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.
-
Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival.
-
Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?
-
Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer.
-
Survival in women with ovarian cancer with and without microsatellite instability.
-
Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells.
-
Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.
-
Symptoms of Women With High-Risk Early-Stage Ovarian Cancer.
-
Synchronous occurrence of gastrointestinal stromal tumour and ovarian neoplasm in a patient presenting with acute cholecystitis.
-
Synchronous primary carcinoma of breast and ovary versus ovarian metastases.
-
Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
-
Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78.
-
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
-
Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells.
-
Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers.
-
T cells in ovarian cancer.
-
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.
-
Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
-
Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.
-
Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation.
-
Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
-
Targeting Dormant Ovarian Cancer Cells In Vitro
and in an In Vivo
Mouse Model of Platinum Resistance.
-
Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia.
-
Targeting ovarian cancer-initiating cells.
-
Targeting slow-proliferating ovarian cancer cells.
-
Targeting the epigenome in ovarian cancer.
-
Telomerase activity in human ovarian carcinoma.
-
Testing for hereditary breast and ovarian cancer in the southeastern United States.
-
The Association Between Body Mass Index and Presenting Symptoms in African American Women with Ovarian Cancer.
-
The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer-A potential therapeutic target.
-
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms.
-
The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms.
-
The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
-
The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3).
-
The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer.
-
The association between progesterone receptor expression and survival in women with adult granulosa cell tumors.
-
The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies.
-
The biology of ovarian cancer.
-
The costs of adding laparoscopy to the management of advanced stage epithelial ovarian cancer.
-
The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.
-
The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists?
-
The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines.
-
The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells.
-
The effectiveness of ovarian cancer screening. A decision analysis model.
-
The genetic attributable risk of breast and ovarian cancer.
-
The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases.
-
The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.
-
The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer.
-
The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
-
The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers.
-
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.
-
The prognostic significance of angiogenesis in epithelial ovarian carcinoma.
-
The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.
-
The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study.
-
The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
-
The rise of genomic profiling in ovarian cancer.
-
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
-
The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma.
-
The role of peptide growth factors in epithelial ovarian cancer.
-
The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.
-
The steroid profile of a virilizing ovarian tumor.
-
The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42.
-
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.
-
Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.
-
Thrombocytopenia in association with a wandering spleen.
-
Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
-
Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer.
-
Top 10 Tips Palliative Care Clinicians Should Know When Caring for Patients with Ovarian Cancer.
-
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
-
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
-
Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha.
-
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.
-
Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk.
-
Transforming growth factor-beta differentially inhibits epithelial ovarian carcinoma cells from primary and metastatic isolates without up-regulation of p21WAF1.
-
Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites.
-
Transhiatal esophagogastrectomy for an isolated ovarian cancer metastasis to the esophagus.
-
Transperitoneal Versus
Extraperitoneal Laparoscopic Lymphadenectomy for Gynecological Malignancies: A Systematic Review and Meta-analysis.
-
Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer.
-
Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity.
-
Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers.
-
Tubal ligation and fatal ovarian cancer in a large prospective cohort study.
-
Tubal ligation and ovarian cancer risk in African American women.
-
Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies.
-
Tubal ligation, hysterectomy, and risk of ovarian cancer.
-
Tubal ligation, hysterectomy, and risk of ovarian cancer.
-
Tumor marker CA-125 as an evaluator and response indicator in ovarian cancer: its quantitative correlation with tumor volume.
-
Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression.
-
Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
-
Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor.
-
U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
-
Ultrastructure of primary and metastatic ovarian carcinoids: analysis of 11 cases.
-
Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer.
-
Unilateral luteoma of pregnancy mimicking a malignant ovarian mass on magnetic resonance and ultrasound.
-
Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer.
-
Urinary cyclic adenosine monophosphate as an aid in the diagnosis of hyperparathyroidism.
-
Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.
-
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.
-
Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment.
-
Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism.
-
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
-
Vacuum-assisted closure for cutaneous gastrointestinal fistula management.
-
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.
-
Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues.
-
Validity of models for predicting BRCA1 and BRCA2 mutations.
-
Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer.
-
Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.
-
Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.
-
Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer.
-
Vascular leukocytes contribute to tumor vascularization.
-
Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer.
-
Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies.
-
Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
-
Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women.
-
Vulnerable Older Adults With Ovarian Cancer-Time to Stop Undertreating.
-
Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
-
What Women and Their Physicians Need to Know About the UKCTOCS Study and Ovarian Cancer Screening.
-
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.
-
Whole-Genome and Segmental Homozygosity Confirm Errors in Meiosis as Etiology of Struma Ovarii.
-
Women's Experiences After Ovarian Cancer Surgery: Distress, Uncertainty, and the Need for Occupational Therapy.
-
XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.
-
Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk.
-
Yin yang 1 modulates taxane response in epithelial ovarian cancer.
-
[Expectations and defeat in the treatment of epithelial cancer of the ovary].
-
p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers.
-
p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry.
-
p53, c-erbB2, and PCNA status in benign, proliferative and malignant ovarian surface epithelial neoplasms: a study of 75 cases.
-
p53-based gene therapy of ovarian cancer: magic bullet?
-
rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.
-
Keywords of People
-
Berchuck, Andrew,
James M. Ingram Distinguished Professor of Gynecologic Oncology,
Obstetrics and Gynecology, Gynecologic Oncology
-
Bradford, William Dalton,
Professor of Pathology,
Pathology
-
Cianciolo, George James,
Associate Professor Emeritus of Pathology,
Pathology
-
Halabi, Susan,
Professor of Biostatistics & Bioinformatics,
Biostatistics & Bioinformatics
-
Moorman, Patricia Gripka,
Professor Emeritus in Family Medicine and Community Health,
Duke Cancer Institute
-
Reed, Shelby Derene,
Professor in Population Health Sciences,
Duke Science & Society
-
Sullivan, Daniel Carl,
Professor Emeritus of Radiology,
Radiology